
Accolate is owned in the United States by Strides Pharma Science Limited, an Indian pharmaceutical company listed on the National Stock Exchange of India (STAR). Strides Pharma International AG holds the US New Drug Application for Accolate, which was originally developed by Zeneca and marketed for decades by AstraZeneca. The brand has been withdrawn in the United Kingdom, Ireland, and Europe, and its US listing was discontinued in March 2026.
Parent Company
Acquired
2023
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Accolate | Strides Pharma Science Limited | Wholly owned |
Zafirlukast emerged from leukotriene research programs at Zeneca Pharmaceuticals in the early 1990s. Leukotrienes are inflammatory molecules involved in airway constriction and mucus production, and blocking their receptors offered a new, non-steroid approach to asthma control. Zafirlukast became one of the first leukotriene receptor antagonists to reach the market.
The FDA approved Accolate 20 mg tablets on September 26, 1996, for the prophylaxis and chronic treatment of asthma in adults and children five years and older, with a 10 mg strength following in September 1999. The product competed directly with montelukast, marketed by Merck as Singulair, which reached the US market in 1998. Singulair's once-daily dosing proved more convenient than Accolate's twice-daily regimen on an empty stomach, and montelukast became the dominant drug in the class.
Zeneca's merger with Astra AB created AstraZeneca in 1999, and Accolate continued as a mid-tier product in the company's respiratory portfolio. Patent protection eroded through the late 2000s. In 2008, Dr. Reddy's Laboratories filed for generic approval, triggering patent litigation that AstraZeneca pursued in the US District Court for the District of New Jersey. The first generic zafirlukast launched in November 2010.
AstraZeneca gradually divested or discontinued legacy respiratory products as it refocused on oncology and biologics. The company withdrew Accolate from the UK and Ireland at the end of March 2018, citing commercial reasons. Prescribing guidance at the time directed clinicians to transition patients to montelukast or inhaled corticosteroids.
In the United States, the Accolate marketing authorization passed to Strides Pharma International AG. FDA National Drug Code records show Strides marketing the branded product from January 2023 until March 12, 2026, when the listing was discontinued. As of November 2026, Accolate exists primarily as the reference listed drug for the generic zafirlukast market rather than as an actively promoted brand.
Who owns Strides Pharma Science?
Strides is publicly traded on India's NSE (STAR) and BSE (532531). Founder Arun Kumar leads the company as chairman, and ownership is divided among the promoter group, institutional investors, and public shareholders.
Is Strides Pharma Science publicly traded?
Yes. Strides trades on the National Stock Exchange of India under ticker STAR and on the Bombay Stock Exchange under code 532531. It is not listed on US or European exchanges.
How many brands does Strides Pharma Science own?
Strides owns a broad portfolio of generic and branded pharmaceutical products rather than consumer-style brands. Its notable US asset is the new drug application for Accolate, the asthma medicine whose American rights it holds after transfer from AstraZeneca.
Where is Strides Pharma Science headquartered?
The company is headquartered in Bengaluru, Karnataka, India, and operates manufacturing sites in India along with international facilities supporting its US, regulated-market, and African businesses.
When was Strides Pharma Science founded?
Arun Kumar founded the company in 1990 in Bengaluru. It grew from a domestic Indian pharma firm into a global generics and specialty manufacturer listed on Indian exchanges.
What is Strides Pharma Science's revenue?
Strides reported revenue of approximately INR 48,587 million for fiscal year 2026, making it a mid-sized player among India's listed pharmaceutical companies.
Accolate's withdrawals have been commercial decisions rather than safety actions. AstraZeneca discontinued the product in the UK and Ireland in March 2018 with regulators and prescriber guidance explicitly noting the absence of safety concerns, and Strides discontinued the US listing in March 2026. In both cases, patients were transitioned to montelukast or inhaled corticosteroid alternatives.
The class-level safety discussion around leukotriene antagonists centers on neuropsychiatric effects. The FDA added a boxed warning to montelukast in 2020 regarding serious mental health side effects, and zafirlukast labeling carries related neuropsychiatric event warnings, though post-marketing attention has focused primarily on montelukast. Zafirlukast also carries a known risk of rare but serious liver injury, and its labeling recommends periodic liver function monitoring.
No large-scale product recall of Accolate has been recorded in FDA enforcement databases. The 2008 patent litigation between AstraZeneca and Dr. Reddy's was resolved through standard settlement channels ahead of the first generic launch in November 2010.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Glaxosmithkline | United Kingdom | 1996 | Mass market | United states | All Genders |
Market Positioning: Accolate competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Strides Pharma Science Limited, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by TTAM Research Institute
Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.
23andMe is privately owned, unlike Accolate which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
Adcock Ingram is privately owned, unlike Accolate which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Global Medical Response
America's largest air ambulance membership network, covering more than 3 million members across 38 states, operated by Global Medical Response.
AirMedCare Network is privately owned, unlike Accolate which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Alfa-Pharm CJSC
Armenia's largest pharmaceutical distributor and pharmacy chain, importing medicines from more than 70 global manufacturers since 1996.
Alfa-Pharm is privately owned, unlike Accolate which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by All Family Pharmacy LLC
Boca Raton mail-order pharmacy at allfamilypharmacy.com known for direct-to-consumer access to ivermectin, hydroxychloroquine, and 200-plus medications.
All Family Pharmacy is privately owned, unlike Accolate which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Opella
Over-the-counter allergy relief brand containing fexofenadine, originally developed by Hoechst Marion Roussel and approved by the FDA in 1996. Owned since April 2025 by Opella, the consumer healthcare company carved out of Sanofi and controlled by Clayton, Dubilier and Rice.
Allegra is privately owned, unlike Accolate which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Consumer DNA testing brand now run as a nonprofit under TTAM Research Institute following the 2025 bankruptcy sale of 23andMe Holding Co.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.